TP53 and myelodysplastic syndrome: Patients with del(5q) LR MDS who have received LEN and have evolution of pre-existing or emerging subclones with TP53 mutations are less sensitive to LEN and have a higher rate of disease progression, possibly due to the selective outgrowth of the TP53 mutated stem progenitor cells [61,62,63,64].